Review Article
Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
Table 4
Phase III clinical trials of FGFR-targeting agents.
| Agent |
Target | Type of cancer | Phase | Combined regimen (comparative arm) | Status or result | Reference |
| Cediranib (AZD2171) | FGFR and VEGFR | CRC | III | FOLFOX or CAPOX (FOLFOX or CAPOX + placebo) | Negative on OS | [59] | CRC | III | FOLFOX (FOLFOX + bevacizumab) | Negative on PFS | [60] | NSLSC | III | Carboplatin + paclitaxel (carboplatin + paclitaxel + placebo) | Negative on PFS/OS | [61] |
| Brivanib (BMS582664) | FGFR and VEGFR | CRC (wild-type KRAS) | III | Cetuximab (cetuximab + placebo) | Negative on OS | [62] | HCC | III | None (sorafenib) | Negative on OS | [63] | HCC | III | None (placebo) | Negative on OS | [64] |
| Dovitinib (TKI258) | FGFR, VEGFR, PDGFR, FLT-3, KIT, and CSF-1 | RCC | III | None (sorafenib) | Negative on PFS | [65] |
| Nintedanib (BIBF1120) | FGFR, VEGFR, PDGFR, FLT-3, and LCK | NSCLC | III | Docetaxel (docetaxel + placebo) | Positive on PFS | [66] |
| Lenvatinib (E7080) |
FGFR, VEGFR, and
PDGFR | HCC | III | None (sorafenib) | Ongoing | [68] | Thyroid | III | None (placebo) | Ongoing | [69] |
| Orantinib (TSU68) | FGFR, VEGFR, and PDGFR | HCC | III | None (placebo) | Suspended | [70] |
|
|
CRC: colorectal cancer; NSCLC: non-small-cell lung cancer; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; CAPOX: capecitabine + leucovorin + oxaliplatin; RFS: relapse-free survival; OS: overall survival.
|